Researchers who work with tiny drug carriers known as lipid nanoparticles have developed a new type of material capable of reaching the lungs and the eyes, an important step toward genetic therapy for hereditary conditions like cystic fibrosis and inherited vision loss.
Amylyx reveals full data that drove pivotal failure for ALS drug: #AAN24
Amylyx outlined the scope of its Phase 3 defeat, demonstrating the extent to which its now-withdrawn ALS drug Relyvrio failed to separate itself from placebo.
April 17, 2024